1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Buying ZS Pharma Could Give AstraZeneca Best-In-Class Blockbuster

 
• By Sten Stovall

Buying California-based ZS Pharma for $2.7bn gives AstraZeneca PLC a potential blockbuster already by next year, adds substance to the pure pharma's offerings for cardiovascular and metabolic disease, and should support its return to growth strategy, analysts say.

Buying California-based ZS Pharma for $2.7bn gives AstraZeneca PLC a potential blockbuster already by next year, adds substance to the pure pharma's offerings for cardiovascular and metabolic disease, and should support its return to growth strategy, analysts say.

Britain's second biggest drug maker apparently outbid Switzerland's Actelion Pharmaceuticals Ltd. to buy ZS Pharma Inc., a victory that brings with it the California-based group's ion trap development program and access to the potassium-binding compound ZS-9, a potential best-in-class treatment for hyperkalaemia, a condition characterized by high levels of potassium in the blood linked with increased mortality in chronic kidney disease and coronary heart failure

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 
• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

Sebela’s Tegoprazan Poised For GERD Market

 
• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

 
• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.

More from Therapy Areas

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.